EDUCATION/TRAINING

• 1992-1999      Xi’an Medical University, China ，Medicine ，Master of Medicine

• (equivalent to M.D. in U.S)

• 2001-2004      Shanghai Institute of Hematology Ruijin Hospital affiliated to Shanghai Second Medical University, China ，Hematology, Internal Medicine ，Ph.D.

• 2004-2009      Temple University School of Medicine, Sol Sherry Thrombosis Research Center. Philadelphia, PA. ，Thrombosis & Biochemistry ，Postdoctoral Fellow

Professional membership

Positions

• Shanghai Jiaotong University School of Medicine ， Associate Scientist Department of Laboratory Medicine ，12.2015~present

• Temple University School of Medicine ，Assistant Scientist Sol Sherry Thrombosis Research Center，9.2009-12.2015

• Temple University School of Medicine ，Postdoctoral Fellow Sol Sherry Thrombosis Research Center，10.2004-9.2009

• Shaanxi Provincial People’s Hospital，Resident, Specialized in hematology & oncology，7.1999-9.2001

Biography

• My major research interests are on the mechanism of haemostasis and coagulation and our research team have been primarily working on the structure and function of coagulation and anticoagulation factors. We have disclosed the molecular pathogenesis of thrombophilia and hemophilia by deciphering the function and structural implication of mutations of encoding genes. Our research findings revealed how the balance of the pro- and anti- coagulation was maintained and pathological outcome when the balance was interrupted. By incorporation of laboratory research in the management of patients with bleeding and thrombotic disorders, we are able to make precision diagnosis and establish individualized treatment accordingly. Furthermore, with the identification of the rare gain of function mutation, we have developed novel gene therapy strategy, which provides hope the cure of the hemophilia.

Awards

• The National Award for Science and Technology Advancement (second class)      2007

• (Hongli Wang, Xuefeng Wang, Qiulan Ding, Zhenyi Wang, Wenbin Wang, Yi Fang, Xiaohong Cai, Wenman Wu, Qihua Fu, Xiangfan Liu. The Clinical and basic research of congenital disorder of coagulation and anticoagulation factors)

• The award Science and Technology Advancement (First Class)  2004

• (Hongli Wang, Xuefeng Wang, Zhengyi Wang, Qihua Fu, Qiulan Ding, Wenman Wu, Baohua Duan, Rongfu Zhou, Wenbin Wang)

Selected Peer-Reviewed Publications

• Yeling Lu, Zhenping Chen, Jing Dai , Xi Wu, Hao Gu , Zekun Li  , Jian Li , Qiulan Ding, Wenman Wu, Runhui Wu , Xuefeng Wang . Maternal Microchimerism Protects Hemophilia A Patients from Inhibitor Development. Blood Adv. 2020;4(9):1867-1869

• Wenman Wu , Lin Xiao , Xi Wu,  Xiaoling Xie  , Ping Li , Changming Chen , Zhaoyue Zheng  , Jiangang Ai , Alexander Valencia , Birong Dong , Qiulan Ding , Biao Dong , Xuefeng Wang. Factor IX Alteration p.Arg338Gln (FIX Shanghai) Potentiates FIX Clotting Activity and Causes Thrombosis. Haematologica. 2020; haematol.2019.216713.

• Wu, Xi； Dai, Jing； Xu，Xiaoqian; Li, Fang; Li, Lei; Lu, Yeling; Xu,Qin; Ding, Qiulan; Wu, Wenman*; Wang, Xuefeng*; Prothrombin Arg541Trp Mutation Leads to Defective PC (Protein C) Pathway Activation and Constitutes a Novel Genetic Risk Factor for Venous Thrombosis , Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40(2): 483-494.

• Li, Fang; Chen, Changming; Qu, Si-Ying; Zhao, Ming-Zhu; Xie, Xiaoling; Wu, Xi; Li, Lei; Wang, Xuefeng; Ding, Qiulan; Xu, Qin*; Wei, Dong-Qing*; Wu,Wenman*; The Disulfide Bond between Cys22 and Cys27 in the Protease Domain Modulate Clotting Activity of Coagulation Factor X , Thrombosis and Haemostasis, 2019, 119(6): 871-881.

• Wu, Wenman; Sinha, Dipali; Shikov, Sergei; Yip, Calvin K; Walz, Thomas;Billings, Paul C; Lear, James D; Walsh, Peter N*; Factor XI homodimer structure is essential for normal proteolytic activation by factor XIIa, thrombin, and factor XIa., Journal of Biological Chemistry, 2008, 283(27): 18655-18664

• Navaneetham, Duraiswamy#; WU, WENMAN#; Li, Hongbo; Sinha, Dipali; Tuma,Ronald; Walsh, Peter*; P1 and P2′ site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor, J Biochem, 2013, 153(2): 221-231.

• Wu, Wenman#; Li, Hongbo#; Navaneetham, Duraiswamy; Reichenbach, Zachary;Tuma, Ronald; Walsh, Peter*; The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis., Blood, 2012, 120(3): 671-677

• Naifang Ye, Zhenzhen Liu, Guanqun Xu, Xuefeng Wang, Fang Wu, Xiaoqian Xu, Wenman Wu. Inhibitor Eradication and Bleeding Management of Acquired Hemophilia A: A Single Center Experience in China. Hematology. 2019 ;24(1):631-636.

• Xiaoling Xie, Changming Chen, Qian Liang, Xi Wu, Xuefeng Wang, Wenman Wu, Qiulan Ding. Characterization of Two Large Duplications of F9 Associated With Mild and Severe Haemophilia B, Respectively. Haemoophilia. 2019;25(3):475-483

• Changming Chen, Xiaoling Xie, Xi Wu, Yeling Lu, Xuefeng Wang, Wenman Wu, Yiqun Hu, Qiulan Ding. Complex Recombination With Deletion in the F8 and Duplication in the TMLHE Mediated by int22h Copies During Early Embryogenesis. Thromb Haemost. 2017 ;117(8):1478-1485

• Xi Wu, Lei Li, Qiulan Ding, Xuefeng Wang, Fang Wu, Wenman Wu. Screening and Functional Exploration of Prothrombin Arg596 Related Mutations in Chinese Venous Thromboembolism Patients. J Clin Pathol. 2018;71(7):614-619

• Yeling Lu, Xi Wu, Jing Dai, Qiulan Ding, Wenman Wu, Xuefeng Wang. The Characteristics and Spectrum of F9 Mutations in Chinese Sporadic Haemophilia B Pedigrees. Haemophilia. 2019 ;25(2):316-323

• Xi Wu, Qiulan Ding, Xuefeng Wang, Jing Dai, Wenman Wu. The Prevalence of Heterozygous F12 Mutations in Chinese Population and Its Relevance to Incidents of Thrombosis. BMC Med Genet. 2018;19(1):50

• Siyu Ma, Changming Chen, Qian Liang, Xi Wu, Xuefeng Wang, Wenman Wu, Yan Liu, Qiulan Ding. Phenotype and Genotype of FXIII Deficiency in Two Unrelated Probands: Identification of a Novel F13A1 Large Deletion Mediated by Complex Rearrangement. Orphanet J Rare Dis. 2019;14(1):182